CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Dr Leslie on the Efficacy of Axi-Cel in Relapsed/Refractory MZL

January 31st 2025

Lori A. Leslie, MD, discusses efficacy data from the phase 2 ZUMA-5 trial evaluating axi-cel in relapsed/refractory marginal zone lymphoma.

Dr Patel on Second Primary Cancer Prevention Strategies After CAR T-Cell Therapy

January 31st 2025

Shyam A. Patel, MD, PhD, discusses secondary prevention strategies that may mitigate the risk of developing SPCs after receipt of CAR T-cell therapy.

Dr Dahiya on the Pathobiology of Second Primary Cancers After CAR T-Cell Therapy

January 31st 2025

Saurabh Dahiya, MD, FACP, details the pathobiology of second primary cancers following receipt of CAR T-cell therapy for hematologic malignancies.

CAR T-Cell Therapy Results in Secondary Primary Cancers in Approximately 4% of Patients

January 31st 2025

Shyam A. Patel, MD, PhD, and Saurabh Dahiya, MD, FACP, detail the pathobiology of SPCs after CAR T-cell therapy and findings from a review on the cancers.

Dr Davila on Efforts to Overcome CD19-Directed CAR T-Cell Therapy Resistance in LBCL

January 30th 2025

Marco Davila, MD, PhD, discusses emerging strategies to overcome resistance to CD19-directed CAR T-cell therapy in aggressive large B-cell lymphoma.

A Close Look at Clinical Trials in Oncology and Beyond: State of Affairs and Industry Progress

January 30th 2025

In this episode, experts discuss progress in cancer clinical trials and the challenges posed by the increasing complexity of therapies and protocols.

Second Primary Cancer Risk Informs the Risk-Benefit Profile of CAR T-Cell Therapies

January 29th 2025

CAR T-cell therapies are associated with a risk for second primary cancers, and mitigation strategies for these toxic effects are warranted and under examination.

Dr Ip on Real-World Data Informing CAR T-Cell Therapy Selection in LBCL

January 29th 2025

Andrew Ip, MD, discusses the importance of making informed clinical decisions when selecting CAR T-cell therapy in older vs younger patients with LBCL.

Dr Brentjens on Efforts to Expand CAR T-Cell Therapy Beyond B-Cell Malignancies

January 21st 2025

Renier Brentjens, MD, PhD, discusses the current landscape of CAR T-cell therapy and ongoing efforts to expand its application beyond B-cell malignancies.

Dr Davila on CD19 CAR T-Cell Therapy Resistance in Large B-Cell Lymphoma

January 20th 2025

Marco Davila, MD, PhD, explains the role of intrinsic tumor drivers in CD19 CAR T-cell therapy resistance in aggressive large B-cell lymphoma.

Lete-Cel Receives FDA Breakthrough Therapy Designation for Advanced Myxoid/Round Cell Liposarcoma

January 16th 2025

The FDA granted breakthrough therapy designation to lete-cel for patients with unresectable or metastatic myxoid/round cell liposarcoma.

Dr Ghobadi on the Efficacy and Safety of WU-CART-007 in R/R T-ALL and LBL

January 10th 2025

Armin Ghobadi, MD, discusses the efficacy and safety of WU-CART-007 in heavily pretreated patients with relapsed/refractory T-ALL and LBL.

Second-Line Axi-Cel Is Efficacious, Safe in Real-World Patients With R/R LBCL

January 6th 2025

Dasom (Caroline) Lee, MD, discusses real-world data for second-line axi-cel in relapsed/refractory large B-cell lymphoma.

Dr van Meerten on the Efficacy and Safety of Brexu-Cel in BTK Inhibitor–Naive R/R MCL

January 6th 2025

Tom van Meerten, MD, PhD, discusses the efficacy and safety of brexucabtagene autoleucel in BTK inhibitor–naive relapsed/refractory MCL.

Anito-Cel Demonstrates Safety and Early Efficacy in R/R Multiple Myeloma

January 6th 2025

Anitocabtagene autoleucel generated durable response in patients with relapsed/refractory multiple myeloma.

Dr Ip on Comparative Findings Between CAR T-Cell Therapies in LBCL

December 20th 2024

Andrew Ip, MD, discusses comparative real-world outcomes of commercial CD19-directed CAR T-cell therapies in large B-cell lymphoma.

Cilta-Cel Leads to 100% MRD-Negativity Rate in High-Risk Smoldering Multiple Myeloma

December 11th 2024

Cilta-cel without induction therapy in high-risk smoldering myeloma marked the first study of CAR T-cell therapy in a precursor cancer setting.

Ide-Cel Shows Real-World Efficacy in CNS Multiple Myeloma

December 10th 2024

Real-world data showed ide-cel was active in patients with central nervous system manifestations of multiple myeloma.

Brexu-Cel Provides Durable Responses in Relapsed/Refractory, BTK-Naive MCL

December 10th 2024

Brexu-cel led to an ORR of 91% in patients with relapsed/refractory MCL who were naive to BTK inhibitors, according to new data from the ZUMA-2 trial.

Cilta-Cel Improves MRD-Negativity Rates in Lenalidomide-Refractory Myeloma

December 10th 2024

Cilta-cel boosted MRD-negativity rates in lenalidomide-refractory multiple myeloma, according to updated results from CARTITUDE-4.